Item 8.01 Other Events.
On August 12, 2021, VYNE Therapeutics Inc. (the "Company") provided an update
regarding its liquidity in its Quarterly Report on Form 10-Q for the quarter
ended June 30, 2021. Additionally, the Company updated the disclosure in Note 1
of the consolidated financial statements from its Form 10-K for the year ended
December 31, 2020 to add disclosure regarding liquidity and capital resources.
The Company's independent registered public accounting firm reissued its report
on the Company's audited consolidated financial statements as of December 31,
2020 and for the year then ended December 31, 2020 to include an emphasis of
matter paragraph regarding liquidity and capital resources as discussed in Note
1 to the consolidated financial statements. The audited consolidated financial
statements and the updated report is included as Exhibit 99.1 to this Current
Report on Form 8-K. Other than as described in the preceding sentence, Exhibit
99.1 does not revise, modify, update or otherwise affect the audited
consolidated financial statements.
Item 9.01. Financial Statements and Exhibits.
The following exhibit is being filed herewith.
Exhibit No. Description
23.1 Consent of PricewaterhouseCoopers LLP
23.2 Consent of Kesselman & Kesselman
99.1 Audited Consolidated Financial Statements
Cover Page Interactive Data File (embedded within the Inline XBRL
© Edgar Online, source Glimpses